RxDoctor Payments DataLook up a doctor →

John Wendt, MD

Cardiovascular Disease · Anderson, SCNPI 1851377816

Payments from drug & device makers

$12,041in general payments, 2019–2025

Across 547 payments — averaging $22.01 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Biotronik Inc.$2K
  • Boston Scientific$1K
  • Novartis$1K
  • Inari Medical, Inc.$1K
  • Johnson & Johnson$950
  • Abbott$810
  • plus $4K from 35 others

What the payments were for

  • Food & beverage$9,790100%
  • Education$150%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$12,041 in reported general payments places this provider in the 75th percentile of 257 cardiovascular disease providers in South Carolina.

See all cardiovascular disease providers in South Carolina

Medicare billing

Part B allowed, 2024
$166,144
Medicare patients
1,392
Services billed
2,455

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban207$238,148
XareltoRivaroxaban53$52,386
EntrestoSacubitril/Valsartan18$24,902
Repatha SureclickEvolocumab22$17,010
Propafenone Hcl ErPropafenone Hcl32$7,309
Carvedilol369$3,199
Valsartan120$2,965
Atorvastatin Calcium199$2,036
Metoprolol Succinate118$1,731
ClopidogrelClopidogrel Bisulfate122$1,542
Ranolazine ErRanolazine11$1,261
Rosuvastatin Calcium95$1,202
Nitroglycerin105$973
Digoxin41$833
Losartan Potassium69$817

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$430$238,148207 claims
Johnson & JohnsonXarelto$950$52,38653 claims
NovartisEntresto$1,146$24,90218 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 257 cardiovascular disease providers in South Carolina.

Other cardiovascular disease in Anderson

See the full list for South Carolina

Where these figures come from

Is this you, or does something look wrong? →